NIMESULIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H12N2O5S
Molecular Weight	308.31
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)NC1=CC=C(C=C1OC2=CC=CC=C2)[N+]([O-])=O

InChI

InChIKey=HYWYRSMBCFDLJT-UHFFFAOYSA-N

InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3

HIDE SMILES / InChI

Description
Sources: https://www.drugbank.ca/drugs/DB04743
Curator's Comment: description was created based on several sources, including http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the second line treatment of acute pain and primary dysmenorrhoea. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf	Inhibitor 8504		17.4 µM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf	Inhibitor 8504		0.6 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute pain 17 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf	Primary		Approved 8583	Nimesulide Approved Use Treatment of acute pain. Primary dysmenorrhoea.
Primary dysmenorrhea 16 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Nimesulide_31/WC500125574.pdf	Primary		Approved 8583	Nimesulide Approved Use Treatment of acute pain. Primary dysmenorrhoea.

C_max

Value	Dose	Analyte	Population
4.58 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7506196/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5099 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27284972/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
75 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2227079/	100 mg single, rectal dose: 100 mg route of administration: Rectal experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
12.06 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22451531/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
65.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9832296/	10 mg single, topical dose: 10 mg route of administration: Topical experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.36 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.3 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.8 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.85 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.17 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.37 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.94 mg/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg 2 times / day multiple, rectal dose: 200 mg route of administration: Rectal experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
49000 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27284972/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
113 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22451531/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9832296/	10 mg single, topical dose: 10 mg route of administration: Topical experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.3 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
22.57 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
54.09 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
81.97 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
43 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
66.13 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24.36 mg × h/L REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg 2 times / day multiple, rectal dose: 200 mg route of administration: Rectal experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.73 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7506196/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27284972/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2227079/	100 mg single, rectal dose: 100 mg route of administration: Rectal experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
4.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22451531/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9832296/	10 mg single, topical dose: 10 mg route of administration: Topical experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.44 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.63 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.73 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.95 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.75 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.81 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.76 h REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2	200 mg 2 times / day multiple, rectal dose: 200 mg route of administration: Rectal experiment type: MULTIPLE co-administered:	NIMESULIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2			NIMESULIDE plasma	Homo sapiens
1% REVIEW https://link.springer.com/chapter/10.1007/3-7643-7410-1_2 \| https://pubmed.ncbi.nlm.nih.gov/7506199/			NIMESULIDE serum	Homo sapiens

Doses

Dose	Population	Adverse events
300 mg 1 times / day multiple, oral Higher than recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14624289/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/14624289/	Sources: https://pubmed.ncbi.nlm.nih.gov/14624289/
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7506187/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7506187/	Sources: https://pubmed.ncbi.nlm.nih.gov/7506187/
40 mg/kg single, oral Overdose Dose: 40 mg/kg Route: oral Route: single Dose: 40 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/	Disc. AE: Hypotension, Hypothermia... AEs leading to discontinuation/dose reduction: Hypotension Hypothermia Hypoglycaemia Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/

AEs

AE	Significance	Dose	Population
Hypoglycaemia	Disc. AE	40 mg/kg single, oral Overdose Dose: 40 mg/kg Route: oral Route: single Dose: 40 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/
Hypotension	Disc. AE	40 mg/kg single, oral Overdose Dose: 40 mg/kg Route: oral Route: single Dose: 40 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/
Hypothermia	Disc. AE	40 mg/kg single, oral Overdose Dose: 40 mg/kg Route: oral Route: single Dose: 40 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11724052/

PubMed

Title	Date	PubMed
Randomized pilot study of nimesulide treatment in Alzheimer's disease.	2002-04-09	11940691
The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.	2002-04	11915030
Evaluation of a selective prostaglandin E receptor EP1 antagonist for potential properties in colon carcinogenesis.	2002-03-26	11911260
A countrywide post-marketing surveillance of nimesulide suspension.	2002-03	11910147
Evaluation of isolated case reports on hepatotoxicity.	2002-02	11936716
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.	2002-02	11872629
Efficacy of nimesulide in pain relief after day care surgery.	2002-02	11867849
The effect of nimesulide on the indomethacin- and ethanol-induced gastric ulcer in rats.	2002-02	11846629
Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism.	2002-02	11840453
N-(3-Phenoxy-4-pyridinio)methanesulfonamidate.	2002-02	11828118
Nimesulide and acute renal failure caused by oxalate precipitation.	2002-02	11812891
Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.	2002-02	11810182
Regulation of prostaglandin production in an immortalized human myometrial cell line by cytokines and non-steroidal anti-inflammatory drugs.	2002-01-10	11750956
Antipyretics in children.	2002-01	11876124
Possible ranitidine-induced cholestatic jaundice.	2002-01	11816250
Lichenoid photodermatitis associated with nimesulide.	2001-12	11903674
Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events.	2001-12	11827360
The effect of alpha-melanocyte stimulating hormone on endotoxin-induced intestinal injury.	2001-12	11786193
Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies.	2001-12	11754119
Hypoglycaemia and hypothermia due to nimesulide overdose.	2001-12	11724052
Effects of nimesulide and its metabolites or manufacturing intermediates on the viability and growth of the human hepatoma HepG2 cell line.	2001-11-09	11758824
Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase.	2001-11-09	11688989
COX-2 inhibitors compared and contrasted.	2001-11	11825322
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001-11	11792017
Fenamates stimulate BKCa channel osteoblast-like MG-63 cells activity in the human.	2001-11	11730088
Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats.	2001-11	11703397
Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.	2001-11	11592955
Inhibition of prostaglandin synthesis and its effect on uterine activity during established premature labor in sheep.	2001-10-26	11677146
The ever-emerging anti-inflammatories. Have there been any real advances?	2001-10-12	11595413
Lipopolysaccharide-mediated immobility in mice: reversal by cyclooxygenase enzyme inhibitors.	2001-10	11838318
Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut.	2001-10	11820457
Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites.	2001-10	11811354
Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis.	2001-10	11695069
Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.	2001-10	11673754
The effects of cervical application of inhibitors of inducible nitric oxide synthase, cyclooxygenase-1, and cyclooxygenase-2 on delivery in rats.	2001-10	11641685
Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay.	2001-10	11576826
Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro.	2001-10	11576568
CaR-mediated COX-2 expression in primary cultured mTAL cells.	2001-10	11553512
Nimesulide-induced acute hepatitis.	2001-09	11573855
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.	2001-09	11570615
Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.	2001-08-24	11525777
Evaluation of efficacy and safety of nimesulide with betacyclodextrin vs nimesulide tablets in osteoarthritis.	2001-08	11881862
Corneal stimulation of MMP-1, -9 and uPA by platelet-activating factor is mediated by cyclooxygenase-2 metabolites.	2001-08	11840344
Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.	2001-08	11694026
Effects of furocoumarins from Cachrys trifida on some macrophage functions.	2001-08	11518028
Fatal hepatoxicity secondary to nimesulide.	2001-07	11549211
NSAID antinociception measured in a chemical and a thermal assay in mice.	2001	11854764
Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.	2001	11759186
Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.	2001	11735667
Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area.	2001	11735663

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 100 mg twice daily and the maximum duration of treatment are 15 days with the shortest duration of treatment recommended.

Route of Administration: Oral

In Vitro Use Guide

Nimesulide (1-100 microM) inhibited platelet aggregation induced by adrenaline (20-200 microM). It also inhibited thromboxane A2 formation by platelets at low concentration (IC50 = 1 microM). However, much lower concentrations of nimesulide (0.01-0.1 microM) potentiated the aggregatory response of subthreshold concentrations of adrenaline (0.2-2 microM).

Name

Type

Language

NIMESULIDE

Official Name

English

NSC-758412

Preferred Name

English

NIMESULIDE [JAN]

Common Name

English

N-(4-NITRO-2-PHENOXYPHENYL)METHANESULFONAMIDE

Systematic Name

English

NIMESULIDE [MI]

Common Name

English

Nimesulide [WHO-DD]

Common Name

English

NIMESULIDE [EP IMPURITY]

Common Name

English

4'-NITRO-2'-PHENOXYMETHANESULFONANILIDE

Systematic Name

English

NIMESULIDE [EP MONOGRAPH]

Common Name

English

R-805

Code

English

nimesulide [INN]

Common Name

English

R 805

Code

English

NIMESULIDE [MART.]

Common Name

English

4-NITRO-2-PHENOXYMETHANESULFONANILIDE

Common Name

English

Classification Tree Code System Code

WHO-ATC

M02AA26